Global Pharmaceuticals & Biotech Top Stock Picks from Analysts

Opus Genetics

Market Cap: US$80.7m

A clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs).

Recce Pharmaceuticals

Market Cap: AU$120.0m

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.

Alterity Therapeutics

Market Cap: AU$119.7m

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

Assertio Holdings

Market Cap: US$77.7m

A pharmaceutical company, provides various products to patients in the United States.

MaaT Pharma

Market Cap: €65.4m

A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.

PMV Pharmaceuticals

Market Cap: US$76.3m

A precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.

Unicycive Therapeutics

Market Cap: US$76.3m

A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.

Artiva Biotherapeutics

Market Cap: US$76.0m

A clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.

Immunic

Market Cap: US$76.0m

A biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.

Cinclus Pharma Holding

Market Cap: SEK 701.8m

A clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China.

Curatis Holding

Market Cap: CHF 59.4m

Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.

Context Therapeutics

Market Cap: US$74.3m

A biopharmaceutical company, develops products for the treatment of solid tumors.

Paradigm Biopharmaceuticals

Market Cap: AU$111.3m

Engages in the research and development of therapeutic products for human use in Australia.

Planet 13 Holdings

Market Cap: CA$100.9m

Planet 13 Holdings Inc., together with its subsidiaries, cultivates and provides cannabis and cannabis-infused products for medical and retail cannabis markets in the United States.

Repare Therapeutics

Market Cap: US$72.6m

A clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States.

Xbrane Biopharma

Market Cap: SEK 670.1m

A biotechnology company, engages in the development, manufacture, and sale of biosimilars.

Medexus Pharmaceuticals

Market Cap: CA$98.5m

Operates as a pharmaceutical company in Canada and the United States.

Insight Molecular Diagnostics

Market Cap: US$70.7m

Operates as a precision diagnostics company in the United States and internationally.

Nutriband

Market Cap: US$69.3m

Develops a portfolio of transdermal pharmaceutical products in the United States.

Cibus

Market Cap: US$68.3m

An agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products.

EZZ Life Science Holdings

Market Cap: AU$103.8m

Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.

Cantargia

Market Cap: SEK 632.7m

A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases.

ECO Animal Health Group

Market Cap: UK£49.8m

ECO Animal Health Group plc, together with its subsidiaries, manufactured and supply animal health products internationally.

Applied Therapeutics

Market Cap: US$67.0m

A clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.

Metagenomi

Market Cap: US$66.8m

A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.

OS Therapies

Market Cap: US$66.7m

A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

Adverum Biotechnologies

Market Cap: US$66.5m

A clinical-stage company, develops gene therapy product candidates to treat ocular diseases.

Aligos Therapeutics

Market Cap: US$66.1m

A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.

MediciNova

Market Cap: US$65.9m

A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.

Prelude Therapeutics

Market Cap: US$64.5m

A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

Genenta Science

Market Cap: US$64.0m

A clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.

Medicenna Therapeutics

Market Cap: CA$88.4m

A clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases.

Immix Biopharma

Market Cap: US$63.1m

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.

Gain Therapeutics

Market Cap: US$62.6m

A biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.

NRx Pharmaceuticals

Market Cap: US$62.5m

A clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain.

MiNK Therapeutics

Market Cap: US$62.2m

A clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.